Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
Omya International AG, 4665 Oftringen, Switzerland.
Eur J Pharm Sci. 2014 Jul 16;58:34-43. doi: 10.1016/j.ejps.2014.03.001. Epub 2014 Apr 2.
Gastroretentive drug delivery systems (GRDDS) play an important role in the delivery of drug substances to the upper part of the gastrointestinal tract; they offer a possibility to overcome the limited gastric residence time of conventional dosage forms.
The aim of the study was to understand drug-release and floatation mechanisms of a floating GRDDS based on functionalized calcium carbonate (FCC). The inherently low apparent density of the excipient (approx. 0.6 g/cm(3)) enabled a mechanism of floatation. The higher specific surface of FCC (approx. 70 m(2)) allowed sufficient hardness of resulting compacts. The floating mechanism of GRDDS was simulated in silico under simulated acidic and neutral conditions, and the results were compared to those obtained in vitro.
United States Pharmacopeia (USP) dissolution methods are of limited usefulness for evaluating floating behavior and drug release of floating dosage forms. Therefore, we developed a custom-built stomach model to simultaneously analyze floating characteristics and drug release. In silico dissolution and floatation profiles of the FCC-based tablet were simulated using a three-dimensional cellular automata-based model.
In simulated gastric fluid, the FCC-based tablets showed instant floatation. The compacts stayed afloat during the measurement in 0.1 N HCl and eroded completely while releasing the model drug substance. When water was used as dissolution medium, the tablets had no floating lag time and sank down during the measurement, resulting in a change of release kinetics.
Floating dosage forms based on FCC appear promising. It was possible to manufacture floating tablets featuring a density of less than unity and sufficient hardness for further processing. In silico dissolution simulation offered a possibility to understand floating behavior and drug-release mechanism.
胃滞留药物递送系统(GRDDS)在将药物递送至胃肠道上部中起着重要作用;它们提供了克服常规剂型胃滞留时间有限的可能性。
本研究的目的是了解基于功能化碳酸钙(FCC)的漂浮 GRDDS 的药物释放和漂浮机制。赋形剂的固有低表观密度(约 0.6 g/cm(3))使其具有漂浮机制。FCC 的更高比表面积(约 70 m(2))允许得到的片剂具有足够的硬度。在模拟酸性和中性条件下,对 GRDDS 的漂浮机制进行了计算机模拟,并将结果与体外结果进行了比较。
美国药典(USP)溶解方法对于评估漂浮剂型的漂浮行为和药物释放的用途有限。因此,我们开发了定制的胃模型来同时分析漂浮特性和药物释放。使用基于三维元胞自动机的模型模拟了基于 FCC 的片剂的计算机模拟溶解和漂浮曲线。
在模拟胃液中,基于 FCC 的片剂立即漂浮。在 0.1 N HCl 中进行测量时,这些片剂保持漂浮状态并完全侵蚀,同时释放模型药物。当用水作为溶解介质时,片剂没有漂浮滞后时间,在测量过程中下沉,导致释放动力学发生变化。
基于 FCC 的漂浮剂型有很大的潜力。有可能制造出密度小于 1 的漂浮片剂,并具有足够的硬度以进行进一步加工。计算机模拟溶解提供了理解漂浮行为和药物释放机制的可能性。